Geographical variation in anti-diabetic prescribing in Ireland in 2013 and 2014: a cross-sectional analysis
Reads0
Chats0
TLDR
There is substantial geographical variation in the prescribing of new T2DM medicines, particularly GLP-1 agonists, in Ireland, and this may not only represent differences in the application of clinical guidelines, but also variation in professional opinion or patient preference.Abstract:
Background Several new medications for type 2 diabetes (T2DM) have been introduced, including dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 receptor (GLP-1) agonists. Variation in the prescribing of these agents has implications for quality, safety and costs. We aimed to investigate geographical variation in the prescribing of anti-diabetic medications in Ireland. Methods Cross-sectional analyses were undertaken on the two main national pharmacy claims databases in Ireland in 2013 and 2014. Direct standardized rates of individual anti-diabetic medication prescribing per 100 000 population were calculated by geographical area. Variation in prescribing was assessed using the systematic component of variation (SCV) and classified as very high (>10), high (5.4-10), moderate (3-5.4) or low (<3). Estimated total costs of prescribing were calculated per geographical area using medication wholesale costs. Results Very high levels of geographical variation of GLP-1 agonists (SCV 11.4 and 10.3 in 2013 and 2014) and moderate variation of DPP-4 inhibitors (SCV 3.8 and 4.1) were found. There was low/moderate variation in the prescribing of sulphonylureas (SVC 2.8 and 3.6) and low variation in prescribing of metformin (SVC 1.7 and 2.0). Geographical variation in Ireland leads to an estimated total wholesale cost differential of €500 000 for GLP-1 agonists, per 100 000 population, between the highest and lowest prescribing areas. Conclusions There is substantial geographical variation in the prescribing of new T2DM medicines, particularly GLP-1 agonists. The prescribing variation which was identified may not only represent differences in the application of clinical guidelines, but also variation in professional opinion or patient preference.read more
Citations
More filters
Journal ArticleDOI
Development of a complex intervention to promote appropriate prescribing and medication intensification in poorly controlled type 2 diabetes mellitus in Irish general practice.
TL;DR: A multifaceted process including an exploration of current evidence and a thorough theoretical understanding of the predictors of the behaviour resulting in the design of a complex intervention to promote the implementation of evidence-based guidelines, through appropriate prescribing and medication intensification in poorly controlled T2DM is described.
Journal ArticleDOI
Low uptake of continuous subcutaneous insulin infusion therapy in people with type 1 diabetes in Ireland: a retrospective cross-sectional study.
TL;DR: Uptake of CSII in people with type 1 diabetes is low in Ireland, particularly in those ≥18 years, and identification of barriers to uptake is required.
Journal ArticleDOI
Prevalence and incidence of type 1 diabetes in Ireland: a retrospective cross-sectional study using a national pharmacy claims data from 2016.
TL;DR: This study provides epidemiological estimates of type 1 diabetes across age groups in Ireland, with the majority of prevalent cases in adults, with a significant positive linear trend for age.
Journal ArticleDOI
Supporting general practitioner-based care for poorly controlled type 2 diabetes mellitus (the DECIDE study): feasibility study and protocol for a pilot cluster randomised controlled trial
Mark E Murphy,Molly Byrne,Fiona Boland,Derek Corrigan,Paddy Gillespie,Tom Fahey,Susan M Smith +6 more
TL;DR: A pilot cluster RCT will establish the feasibility of a complex intervention which aims to support primary care for patients with poorly controlled T2DM in Irish General Practice, and a process evaluation will be performed to determine whether the intervention is delivered as intended.
Journal ArticleDOI
Prescriber Variation in Relation to Prescribing Trends within the Preferred Drugs Initiative in Ireland (2012-2015): An Interrupted Time Series Study Using Latent Curve Models
Ronald McDowell,Ronald McDowell,Kathleen Bennett,Frank Moriarty,Sarah Clarke,Michael J. Barry,Tom Fahey +6 more
TL;DR: Moderate changes in prescribing of the preferred drugs have been observed over the course of the PDI, however, the guidelines have had little impact in reducing variation between prescribers.
References
More filters
Journal ArticleDOI
Small-Area Variations in the Use of Common Surgical Procedures: An International Comparison of New England, England, and Norway
TL;DR: Differences among countries in the methods of organizing and financing care appear to have little relation to the intrinsic variability in the incidence of common surgical procedures among hospital service areas in these countries.
Journal ArticleDOI
Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes
Rodney A. Hayward,Peter D. Reaven,Wyndy L. Wiitala,Gideon Bahn,Domenic J. Reda,Ling Ge,Madeline McCarren,William C. Duckworth,Nicholas V. Emanuele +8 more
TL;DR: Patients with type 2 diabetes who had been randomly assigned to intensive glucose control for 5.6 years had 8.6 fewer major cardiovascular events per 1000 person-years than those assigned to standard therapy, but no improvement was seen in the rate of overall survival.
Journal ArticleDOI
Pharmaceutical industry-sponsored meals and physician prescribing patterns for medicare beneficiaries
Colette DeJong,Thomas Aguilar,Chien-Wen Tseng,Grace A. Lin,W. John Boscardin,R. Adams Dudley +5 more
TL;DR: To study the association between physicians' receipt of industry-sponsored meals, which account for roughly 80% of the total number of industry payments, and rates of prescribing the promoted drug to Medicare beneficiaries, industry payment data and Medicare prescribing records recently became publicly available.
Journal ArticleDOI
Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis.
Suetonia C. Palmer,Dimitris Mavridis,Dimitris Mavridis,Antonio Nicolucci,David W. Johnson,David W. Johnson,Marcello Tonelli,Jonathan C. Craig,Jasjot K. Maggo,Vanessa Gray,Giorgia De Berardis,Marinella Ruospo,Patrizia Natale,Valeria Saglimbene,Sunil V. Badve,Sunil V. Badve,Yeoungjee Cho,Annie-Claire Nadeau-Fredette,Michael Burke,Michael Burke,Labib Faruque,Anita Lloyd,Nasreen Ahmad,Yuanchen Liu,Sophanny Tiv,Natasha Wiebe,Giovanni F.M. Strippoli,Giovanni F.M. Strippoli +27 more
TL;DR: Findings are consistent with American Diabetes Association recommendations for using metformin monotherapy as initial treatment for patients with type 2 diabetes and selection of additional therapies based on patient-specific considerations.
Journal ArticleDOI
Time to tackle unwarranted variations in practice.
TL;DR: US and UK data show that much of the variation in use of healthcare is accounted for by the willingness and ability of doctors to offer treatment rather than differences in illness or patient preference.